Thromboembolic Disorder Treatments
Anticoagulants, antiplatelets, and thrombolytics for the treatment and/or prophylaxis of venous and arterial thrombosis.
Cardiovascular Disease
Anticoagulant Dosing Conversions
Recommended dosing conversions for anticoagulants such as warfarin, heparin, and dabigatran.
Thromboembolic Disorder Treatments: Without DVT/PE
A comparative medication chart of thromboembolic disorder treatments in patients without DVT/PE.
Ultomiris Receives Approval for Atypical Hemolytic Uremic Syndrome
The FDA has approved Ultomiris (ravulizumab-cwvz; Alexion) for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adult and pediatric patients aged 1 month and older.
Rivaroxaban Compared With Warfarin in Morbidly Obese Patients With VTE
Results from a new real-world study evaluating rivaroxaban (Xarelto; Janssen), a factor Xa inhibitor, in morbidly obese patients were recently published in Thrombosis Research. The retrospective cohort study analyzed data from 2 US claims databases (Truven MarketScan Commercial Claims and Encounters database and MarketScan Medicare Supplemental database) to evaluate the clinical and health/economic outcomes of…
Rivaroxaban May Be Safe, Effective for Pediatric VTE Treatment, Says Study
Results of the study showed that the rate of symptomatic recurrent VTE – the primary end point – was similar in both treatment groups with 1.2% of patients experiencing a recurrent event in the rivaroxaban group compared with 3.0% in the standard anticoagulation group.
Thromboembolic Disorder Assessment: DVT/PE
Risk factors, prevention strategies, signs & symptoms, and general treatment options for deep vein thrombosis (DVT) and pulmonary embolism (PE).
Novel Reversal Agent for Ticagrelor Gets FDA’s Breakthrough Tx Designation
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to PB2452 (PhaseBio), an investigational reversal agent for ticagrelor.
Next post in Bleeding Disorders
